씨엔알리서치

359090KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

61.4 / 100

Reference Date: 2026-06-10

Financial Score32.5 / 40

News Sentiment15.9 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Plunged 23.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

CNR Research, established in 1997 as Korea's first CRO, provides clinical trial services for drug development, including Phase I-III trials for regulatory approval and post-market studies (PMS/Phase IV). It maintains the top position among domestic CROs by revenue in 2023 and aims to expand globally through IT solution development and oncology trial expertise.

Number of Employees

522people

Average Salary

58.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.22Industry Average 48.808.0Point

Half of industry avg (excellent)

PBR

0.66Industry Average 1.437.0Point

Half of industry avg (excellent)

ROE

2.15Industry Average 0.947.0Point

2.3x industry avg (excellent)

Debt Ratio

5.27Industry Average 12.516.5Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼51.8% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 1Negative 1Average Sentiment Score 63.8

Positive
씨엔알리서치, 국내 1호 디지털치료기기 美 임상 수주
씨엔알리서치가 미국에서 불면증 디지털치료기기의 임상 수주를 통해 글로벌 시장 진출 기회를 확대했다.
Negative
씨엔알리서치, 주식병합으로 5일부터 매매거래 정지
씨엔알리서치의 주식병합으로 인한 매매거래 정지로 인해 투자자들의 불안감이 증가하고 있다.
Neutral
씨엔알리서치, ‘베이지안 접근법’ 임상 전략 웨비나 개최
씨엔알리서치가 베이지안 접근법 웨비나를 개최하여 전문 지식 공유에 초점을 맞추었으나, 직접적인 주가 영향은 제한적.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 550Won52-week high 1,10252-week low 511

1-month return0.0Point

1m -23.08% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-06-02
Neutral분기보고서 (2026.03)2026-05-14